Roflumilast
Treatment for Chronic Bronchitis
Typical Dosage: 500 mcg once daily
Effectiveness
68%
Safety Score
45%
Clinical Trials
5
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
500 mcg once daily
Time to Effect
3-6 months
Treatment Duration
Lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
18(Treat 18 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
13(Treat 13 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$9,000
Monitoring:$600
Side Effect Mgmt:$300
Total Annual:$9,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$40,000/QALY
QALYs Gained
0.05
Outcome-Based Costs
Cost per Responder
$18,000
Roflumilast Outcomes
for Chronic Bronchitis
Efficacy Outcomes
Overall Effectiveness
+68%
Response Rate
+55%
Common Side Effects
Diarrhea
+9%
Nausea
+5%
Weight decrease
+4%
Headache
+3.5%
Insomnia
+2.5%
Sources:
Active Clinical Trials
3 active trials recruiting for Roflumilast in Chronic Bronchitis
Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
NCT04069312ACTIVE NOT RECRUITINGPHASE4
1.03K participants
INTERVENTIONAL
Birmingham, United States +28 more
Started: Feb 11, 2020
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
NCT04636814ACTIVE NOT RECRUITINGPHASE3
3.97K participants
INTERVENTIONAL
Andalusia, United States +459 more
Started: Jul 12, 2021
The Italian Registry of Patients with Chronic Obstructive Pulmonary Disease
NCT06652776ENROLLING BY INVITATION
10K participants
OBSERVATIONAL
Milan, Italy
Started: Sep 30, 2024
Completed Clinical Trials
1 completed trial for Roflumilast in Chronic Bronchitis
The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
NCT03073798COMPLETEDPHASE4
12 participants
INTERVENTIONAL
Started: Mar 18, 2013